2021
DOI: 10.3390/life11090896
|View full text |Cite
|
Sign up to set email alerts
|

BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects

Abstract: We aimed to investigate neutralizing antibody titers (NtAbT) to the P.1 and B.1 SARS-CoV-2 variants in a cohort of healthy health care workers (HCW), including 20 previously infected individuals tested at baseline (BLinf, after a median of 298 days from diagnosis) and 21 days after receiving one vaccine dose (D1inf) and 15 uninfected subjects tested 21 days after the second-dose vaccination (D2uninf). All the subjects received BNT162b2 vaccination. D1inf NtAbT increased significantly with respect to BLinf agai… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 42 publications
0
1
0
Order By: Relevance
“…The two mRNA vaccines, BNT162b2 and mRNA-1273, maintained equivalent protection efficacy against Alpha 327 331 Beta, 221 , 330 , 332 , 333 Gamma, 327 , 330 , 333 , 334 and Delta 221 , 327 , 330 , 335 337 variants in all major endpoints, with only a moderate decrease in protection against documented Beta variant infection. 338 For the adenovirus vaccine AZD1222, VE for Beta variant symptomatic infection was found to drop dramatically to 10.4% (95% CI: −76.8 to 54.8) in a prospective study performed in South Africa among 2026 participants, 328 while the protection against Alpha, 330 , 339 , 340 Gamma, 330 , 334 and Delta 339 , 341 343 variant was mostly retained.…”
Section: Molecular Characteristics Of Sequence and The Encoded Protei...mentioning
confidence: 94%
“…The two mRNA vaccines, BNT162b2 and mRNA-1273, maintained equivalent protection efficacy against Alpha 327 331 Beta, 221 , 330 , 332 , 333 Gamma, 327 , 330 , 333 , 334 and Delta 221 , 327 , 330 , 335 337 variants in all major endpoints, with only a moderate decrease in protection against documented Beta variant infection. 338 For the adenovirus vaccine AZD1222, VE for Beta variant symptomatic infection was found to drop dramatically to 10.4% (95% CI: −76.8 to 54.8) in a prospective study performed in South Africa among 2026 participants, 328 while the protection against Alpha, 330 , 339 , 340 Gamma, 330 , 334 and Delta 339 , 341 343 variant was mostly retained.…”
Section: Molecular Characteristics Of Sequence and The Encoded Protei...mentioning
confidence: 94%